ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) announced a conference call and webcast scheduled for August 9, 2022, at 8:30 a.m. ET to disclose its Q2 2022 financial results and share business updates. The call will provide investors with insights into the company’s performance and operations. ADC Therapeutics specializes in targeted antibody drug conjugates for cancer treatment, including the FDA-approved ZYNLONTA for diffuse large B-cell lymphoma, and ongoing developments in its ADC pipeline.

Positive

• ADC Therapeutics is a commercial-stage biotechnology company focused on improving cancer treatment.
• The FDA approval of ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma enhances ADC Therapeutics' position in the market.

Negative

• None.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m. ET to report financial results for the second quarter 2022 and provide business updates.

To access the conference call, please register here. Registrants will receive the dial-in number and unique PIN. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under “Events and Presentations” in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA^® (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005270/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

Tel.: +44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

Tel.: +1 917-288-7023

Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

Tel.: +1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When will ADC Therapeutics announce its Q2 2022 financial results?

ADC Therapeutics will announce its Q2 2022 financial results on August 9, 2022, at 8:30 a.m. ET.

What is ZYNLONTA, and why is it significant for ADC Therapeutics?

ZYNLONTA is an FDA-approved ADC for treating relapsed or refractory diffuse large B-cell lymphoma, marking a key product in ADC Therapeutics' oncology portfolio.

How can I access the ADC Therapeutics conference call?

To access the ADC Therapeutics conference call, you can register via their official website or attend the live webcast in the Investors section.

What is the focus of ADC Therapeutics' research and development?

ADC Therapeutics specializes in next-generation targeted antibody drug conjugates, particularly for hematologic malignancies and solid tumors.